Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 60

Sort by

Sort Order Select

Journal Articles

Phase 1 First-in-Human Trial of AMV564, a Bivalent Bispecific (2:2) CD33/CD3 T-Cell Engager, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

Peter Westervelt, MD PhD, Jorge E. Cortes, MD, Jessica K. Altman, Meixiao Long, MD, Vivian G. Oehler, MD, Ivana Gojo, MD, Jeanmarie Guenot, PhD, Patrick Chun, MD, Gail J. Roboz, MD

Blood (2019) 134 (Supplement_1): 834.

https://doi.org/10.1182/blood-2019-129042

Published: 2019

Journal Articles

First-in-Human, Phase 1/2 Trial to Assess the Safety and Clinical Activity of Subcutaneous GEN3013 (DuoBody ® -CD3×CD20) in B-Cell Non-Hodgkin Lymphomas

Pieternella Lugtenburg, MD PhD, Rogier Mous, MD PhD, Michael Roost Clausen, Martine E.D. Chamuleau, Peter Johnson, MDFRCP, Kim Linton, PhD, Simon Rule, Roberto S Oliveri, MD PhD, Dena DeMarco, Ida H Hiemstra, PhD, Guang Chen, Ada Azaryan, Manish Gupta, Tahamtan Ahmadi, Martin Hutchings, MD PhD

Blood (2019) 134 (Supplement_1): 758.

https://doi.org/10.1182/blood-2019-121460

Published: 2019

Journal Articles

Rapid Infusion Daratumumab Is Safe in Patients with AL Amyloidosis

Nathaniel Rosko, PharmD, Hanjie Mo, PharmD, Joslyn Rudoni, PharmD, Caitlin Siebenaller, PharmD, Sarah S Lee, MD, Rajshekar Chakraborty, MD, Beth M. Faiman, PhDCNP, Jack Khouri, MD, Alex V. Mejia Garcia, MD, Christy J. Samaras, DO, Faiz Anwer, MD, Jason Valent, MD

Blood (2019) 134 (Supplement_1): 1838.

https://doi.org/10.1182/blood-2019-124775

Published: 2019

Journal Articles

UK Single Institution Experience of Mastocytosis: Guy's and St Thomas' NHS Foundation Trust

Clare Oni, MD, Mufaddal Moonim, MD, Joana Desterro, MD, Clive Grattan, MD, Natalia Curto-Garcia, MD, Claire Woodley, Monika Ciesielska, Deimante Drasutyte, Yvonne Francis, Jennifer O'Sullivan, MD, Thompson Olaoni, Anna Green, MD, Miki Yurina, MD, Mark Ong, MD, Nick C.P. Cross, Professor, Donal P. McLornan, MB, BCh (Hons), MRCP, PhD FRCPath, Deepti Radia

Blood (2019) 134 (Supplement_1): 2960.

https://doi.org/10.1182/blood-2019-130477

Published: 2019

Journal Articles

Pioneer: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Avapritinib in Patients with Indolent or Smoldering Systemic Mastocytosis with Symptoms Inadequately Controlled with Standard Therapy

Blood (2019) 134 (Supplement_1): 2950.

https://doi.org/10.1182/blood-2019-126035

Published: 2019

Journal Articles

Extensive Metabolic Correction of Hurler Disease By Hematopoietic Stem Cell-Based Gene Therapy: Preliminary Results from a Phase I/II Trial

Bernhard Gentner, MD, Maria Ester Bernardo, MD PhD, Francesca Tucci, MD, Erika Zonari, PhD, Francesca Fumagalli, MD, Silvia Pontesilli, MD, Serena Acquati, PhD, Paolo Silvani, MD, Fabio Ciceri, MD, Attilio Rovelli, MD, Giancarlo La Marca, PhD, Rossella Parini, MD, Silvia Gregori, PhD, Eugenio Montini, PhD, Luigi Naldini, MD PhD, Alessandro Aiuti, MD PhD

Blood (2019) 134 (Supplement_1): 607.

https://doi.org/10.1182/blood-2019-128805

Published: 2019

Journal Articles

A Phase I/II Study of Lenalidomide Plus Obinutuzumab in Relapsed Indolent Lymphoma

Nathan H Fowler, MD, Loretta J. Nastoupil, MD MSc, Collin Chin, MBBS, Paolo Strati, MD, Fredrick B. Hagemeister, MD, Luis E. Fayad, MD, Jason R. Westin, MD, Sheryl G Forbes, Janine Arafat, Lei Feng, MS, Ranjit Nair, MBBS,MD, Raphael E Steiner, MD, Felipe Samaniego, MD, Sattva S Neelapu, MD

Blood (2019) 134 (Supplement_1): 348.

https://doi.org/10.1182/blood-2019-131045

Published: 2019

Journal Articles

The iR 2 Regimen(Ibrutinib, Lenalidomide, and Rituximab) Is Active with a Manageable Safety Profile in Patients with Relapsed/Refractory Non-Germinal Center-like Diffuse Large B-Cell Lymphoma

Blood (2018) 132 (Supplement 1): 402.

https://doi.org/10.1182/blood-2018-99-111163

Published: 2018

Journal Articles

Evaluation of Infusion Reactions in Patients Receiving Daratumumab Post-Implementation of an Augmented Pre- and Peri-Medication Regimen

Patrick McBride, PharmD, Houry Leblebjian, PharmD, Paul Richardson, Jacob Laubach, MD, Hillary Prescott, PharmD

Blood (2018) 132 (Supplement 1): 3234.

https://doi.org/10.1182/blood-2018-99-111361

Published: 2018

Journal Articles

Evaluation of Intravenous Diphenhydramine Use in Patients with Sickle Cell Vaso-Occlusive Crisis

Ifeyinwa Osunkwo, MD MPH, Shelby Merchant, PharmD, Rachel Crawford, PharmD, BCPS, Katherine Rector, PharmD, BCPS, Justin Arnall, PharmD, CPP, BCOP, James T Symanowski, PhD, Padmaja Veeramreddy, MD

Blood (2018) 132 (Supplement 1): 3575.

https://doi.org/10.1182/blood-2018-99-116848

Published: 2018

Journal Articles

Safety and Efficacy of Ibrutinib in Combination with Rituximab and Lenalidomide in Previously Untreated Subjects with Follicular and Marginal Zone Lymphoma: An Open Label, Phase II Study

Loretta J. Nastoupil, MD, Hun Ju Lee, MD, F. B. Hagemeister, MD, Jason R. Westin, MD, Felipe Samaniego, MD, Lei Feng, MS, Jiffin John, Sheryl G Forbes, Luis E. Fayad, Michael R Green, PhD, R. Eric Davis, MD, Sattva S. Neelapu, MD, Nathan H. Fowler, MD

Blood (2018) 132 (Supplement 1): 447.

https://doi.org/10.1182/blood-2018-99-113721

Published: 2018

Journal Articles

AK002, a Novel Humanized Monoclonal Antibody to Siglec-8, Inhibits Mast Cell Activity and Depletes Eosinophils in Ex Vivo Bone Marrow Tissue from Patients with Systemic Mastocytosis

Bradford A Youngblood, PhD, Emily C Brock, John Leung, Alan T Chang, Christopher Bebbington, PhD, Nenad Tomasevic, PhD

Blood (2018) 132 (Supplement 1): 1104.

https://doi.org/10.1182/blood-2018-99-119232

Published: 2018

Journal Articles

All Itching Is Not Benign; A Case of Refractory Hypereosinophilic Syndrome Treated with Off Label CD52 Inhibitor-Alemtuzumab

Rehan Ansari, MD, Elva Nora Osuna Salazar, MD, Nabeel Sarhill, MD, Laura E Garcia, MD, James Hanley, MD

Blood (2018) 132 (Supplement 1): 5485.

https://doi.org/10.1182/blood-2018-99-118271

Published: 2018

Journal Articles

Assisted Administration of Subcutaneous Rituximab to the Patient's Home. Significant Reduction of Indirect Costs Incurred By Care Recipients and Unpaid Caregivers Together with a Total Adherence to the Treatment Schedule and Same Safety

Francesco Iuliano, MD, Eleonora Iuliano, MD, Marco Rossi, MD

Blood (2018) 132 (Supplement 1): 5869.

https://doi.org/10.1182/blood-2018-99-118756

Published: 2018

Journal Articles

Absence of Silent Inactivation Using Intravenous Pegaspargase in Pediatric Acute Lymphoblastic Leukemia

Sarayu Kumar, BA, BSPH, Curtis D Travers, MPH, John Bergsagel, MD, Frank G Keller, MD, Melinda Pauly, MD, Himalee Sabnis, MDMS, Sharon M. Castellino, MD MSc, Glen Lew, MD

Blood (2017) 130 (Supplement 1): 100.

https://doi.org/10.1182/blood.V130.Suppl_1.100.100

Published: 2017

Journal Articles

Use of Premedication Prior to Asparaginase (ASNase) Administration in Pediatric Acute Lymphoblastic Leukemia (ALL): Effect on Treatment Completion Rate

Celine Bernard, MBA, Nathan Rustay, PhD, Kira Mamedov, MD

Blood (2017) 130 (Supplement 1): 5574.

https://doi.org/10.1182/blood.V130.Suppl_1.5574.5574

Published: 2017

Journal Articles

Activity and Safety of Daratumumab Monotheray in Patients with Relapsed and Refractory Multiple Myeloma Requiring Dialysis: Preliminary Results of Spanish, Retrospective, Multicenter Trial

Maria José Cejalvo, Mario Legarda, Eugenia Abella, Elena Cabezudo, Cristina Encinas, Ana García-Feria, Belén Iñigo, Jesús Marín, Paz Ribas, M. Ángeles Ruíz, Javier de la Rubia

Blood (2017) 130 (Supplement 1): 1866.

https://doi.org/10.1182/blood.V130.Suppl_1.1866.1866

Published: 2017

Journal Articles

Application of Autologous Artificial Tears in a Case of an 8-Year-Old Girl with Vernal Keratoconjunctivitis (Spring Catarrh)

Pawel Jozef Laguna, Jolanta Antoniewicz-Papis, Alina Szajkowska, Magdalena Letowska, Tomasz Szczepański, MD PhD, Michal Matysiak, Prof, MD PhD

Blood (2017) 130 (Supplement 1): 4931.

https://doi.org/10.1182/blood.V130.Suppl_1.4931.4931

Published: 2017

Journal Articles

Rituximab Subcutaneous Formulation (SC-R) Is Safe, Effective and Cost-Saving in Patients Suffering from Autoimmune Hemolytic Anemia (AIHA)

Francesco Iuliano, MD, Eleonora Iuliano, MD, Alessia Perricelli, MD, Angelo Pomillo, MD, Maria Luci, MD, Maria Aquila Santoro, MD, Pierosandro Tagliaferri, MD, Pierfrancesco Tassone, MD

Blood (2016) 128 (22): 1269.

https://doi.org/10.1182/blood.V128.22.1269.1269

Published: 2016

Journal Articles

Preliminary Results from a Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Hodgkin Lymphoma

Alex F Herrera, MD, Nancy L Bartlett, MD, Radhakrishnan Ramchandren, MD, Julie M Vose, MD, Alison J Moskowitz, MD, Tatyana A Feldman, MD, Ann S LaCasce, MD, Stephen M Ansell, MD PhD, Craig H. Moskowitz, MD, Keenan Fenton, Kazunobu Kato, MD, Abraham Fong, MD PhD, Ranjana H Advani, MD

Blood (2016) 128 (22): 1105.

https://doi.org/10.1182/blood.V128.22.1105.1105

Published: 2016

NARROW

Phase 1 First-in-Human Trial of AMV564, a Bivalent Bispecific (2:2) CD33/CD3 T-Cell Engager, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

First-in-Human, Phase 1/2 Trial to Assess the Safety and Clinical Activity of Subcutaneous GEN3013 (DuoBody ® -CD3×CD20) in B-Cell Non-Hodgkin Lymphomas

Rapid Infusion Daratumumab Is Safe in Patients with AL Amyloidosis

UK Single Institution Experience of Mastocytosis: Guy's and St Thomas' NHS Foundation Trust

Pioneer: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Avapritinib in Patients with Indolent or Smoldering Systemic Mastocytosis with Symptoms Inadequately Controlled with Standard Therapy

Extensive Metabolic Correction of Hurler Disease By Hematopoietic Stem Cell-Based Gene Therapy: Preliminary Results from a Phase I/II Trial

A Phase I/II Study of Lenalidomide Plus Obinutuzumab in Relapsed Indolent Lymphoma

The iR 2 Regimen(Ibrutinib, Lenalidomide, and Rituximab) Is Active with a Manageable Safety Profile in Patients with Relapsed/Refractory Non-Germinal Center-like Diffuse Large B-Cell Lymphoma

Evaluation of Infusion Reactions in Patients Receiving Daratumumab Post-Implementation of an Augmented Pre- and Peri-Medication Regimen

Evaluation of Intravenous Diphenhydramine Use in Patients with Sickle Cell Vaso-Occlusive Crisis

Safety and Efficacy of Ibrutinib in Combination with Rituximab and Lenalidomide in Previously Untreated Subjects with Follicular and Marginal Zone Lymphoma: An Open Label, Phase II Study

AK002, a Novel Humanized Monoclonal Antibody to Siglec-8, Inhibits Mast Cell Activity and Depletes Eosinophils in Ex Vivo Bone Marrow Tissue from Patients with Systemic Mastocytosis

All Itching Is Not Benign; A Case of Refractory Hypereosinophilic Syndrome Treated with Off Label CD52 Inhibitor-Alemtuzumab

Assisted Administration of Subcutaneous Rituximab to the Patient's Home. Significant Reduction of Indirect Costs Incurred By Care Recipients and Unpaid Caregivers Together with a Total Adherence to the Treatment Schedule and Same Safety

Absence of Silent Inactivation Using Intravenous Pegaspargase in Pediatric Acute Lymphoblastic Leukemia

Use of Premedication Prior to Asparaginase (ASNase) Administration in Pediatric Acute Lymphoblastic Leukemia (ALL): Effect on Treatment Completion Rate

Activity and Safety of Daratumumab Monotheray in Patients with Relapsed and Refractory Multiple Myeloma Requiring Dialysis: Preliminary Results of Spanish, Retrospective, Multicenter Trial

Application of Autologous Artificial Tears in a Case of an 8-Year-Old Girl with Vernal Keratoconjunctivitis (Spring Catarrh)

Rituximab Subcutaneous Formulation (SC-R) Is Safe, Effective and Cost-Saving in Patients Suffering from Autoimmune Hemolytic Anemia (AIHA)

Preliminary Results from a Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Hodgkin Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only